Argos Therapeutics Inc (NASDAQ:ARGS) has earned an average rating of “Hold” from the six analysts that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating and three have issued a hold rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $24.00.
Separately, ValuEngine upgraded Argos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday.
An institutional investor recently bought a new position in Argos Therapeutics stock. Wasatch Advisors Inc. purchased a new position in Argos Therapeutics Inc (NASDAQ:ARGS) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned 1.21% of Argos Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).
Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.00) earnings per share for the quarter.
TRADEMARK VIOLATION WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/02/02/argos-therapeutics-inc-args-given-consensus-recommendation-of-hold-by-brokerages.html.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.